Daya CNS, LLC

SAINT LOUIS, MO · Founded 2013 · CIK 0001689400 · Biotech · Private

Small-molecule therapeutics targeting central and peripheral nervous system diseases

dayacns.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$228K
1 Form D · Nov 2016
119 months since last filing
Contracts
—
No federal contracts on record
Patents
2
0 granted · 2 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$228,310
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2625X1 Biotech Inc.—$235K
2626ZYMTRONIX CATALYTIC SYSTEMS, INC.——
2627HUNTERIAN MEDICINE LLC—$230K
2628Daya CNS, LLC—$228K
2629Zepteon, Inc—$210K
2630VERRA THERAPEUTICS LLC—$205K
2631ELDEC PHARMACEUTICALS INC.—$200K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 4 related persons
  • Raj DevrajDirector
  • Steve HanleyDirector
  • Ragahavan RajagopalanDirector · Executive Officer
  • Walter SmithDirector

Patents

USPTO · 0 granted of 2
  • Pentacyclic Pyridoindolo[b,e]azepine Derivatives And Uses Thereofapplication
  • Pentacyclic Pyridoindolobenz[b,d]azepine Derivatives And Uses Thereofapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.